Jamie is a Managing General Partner with Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Jamie has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.

Jamie has led and served as a board member for many of Frazier’s successful life sciences investments, including Calistoga Pharmaceuticals (co-founder, sold to Gilead), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ:PTLA), Cotherix (sold to Actelion), and Threshold (NASDAQ:THLD). He currently represents Frazier on the boards of Alcresta Pharmaceuticals, Allena Pharmaceuticals, Alpine Immune Sciences, Anaptys Biotech, Aptinyx, Entasis Therapeutics, Merganser Biotech, Millendo Therapeutics (formerly Atterocor), and ProNai Therapeutics (NASDAQ:DNAI).

Jamie received his M.D. and Ph.D. in Biophysics from Stanford University School of Medicine and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston and is board certified in both disciplines. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. In 2011 and 2016, Jamie was named to the Midas List of leading venture capitalists, and in 2013 was recognized by Forbes as one of the top 10 healthcare investors.